Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) has again recommended continuation of the MIV-711 osteoarthritis extension study without modifications based on a review of the accumulated safety data. As part of the MIV-711 phase IIa programme, an independent DMC is periodically scheduled to review the accumulated safety data. Based on the present DMC review of all safety data, including unblinded data from the initial study and data to date from the extension study, the DMC has recommended that the extension